You are using an outdated browser. Please upgrade your browser to improve your experience and security.

VYXEOS administration allows sAML patients time off therapy1

51% of patients received consoldation

of sAML patients received consolidation with VYXEOS in an outpatient setting during the Phase 3 trial2

Learn more about outpatient administration with VYXEOS

Download PDF

VYXEOS dosing and administration schedule1,a,b

  • First induction: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome on Days 1, 3, and 5
  • Second induction (if needed): daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome on Days 1 and 3
    • In patients not achieving a response, start 2 to 5 weeks after first induction
  • First consolidation: daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 liposome on Days 1 and 3
    • 5 to 8 weeks after the start of last induction
  • Second consolidation (if needed): daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 liposome on Days 1 and 3
    • 5 to 8 weeks after the start of first consolidation in patients who do not show disease progression or unacceptable toxicity

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.